Primary Outcomes

Description: Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive)for tumor responses (CR + PR) Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Description: Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive) by evaluating progression-free survival Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

Secondary Outcomes

Description: Progression Free Survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

Description: Overall survival is define as date from time of initial treatment to date of death from any cause.

Description: Frequency and severity as defined by CTCAE v 4.0